Rapport Therapeutics Reports $26.9 Million Net Loss in Q3 2025, Highlights R&D Progress

Rapport Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $26.9 million for the third quarter, compared to a loss of $17.5 million in the same period last year. For the nine months ended September 30, 2025, the net loss totaled $77.7 million, up from $58.3 million in the prior year. Operating expenses for the quarter increased to $30.0 million, a rise from $21.6 million in the previous year, driven primarily by higher research and development costs associated with ongoing clinical trials.

The company’s total operating expenses for the nine months reached $86.6 million, compared to $59.5 million in the same period of 2024. This increase was largely attributed to a $20.8 million rise in research and development expenses, which amounted to $64.5 million for the nine months. The increase in R&D spending was primarily due to costs related to the Phase 2a trial of RAP-219, which is being developed for drug-resistant focal onset seizures, as well as other clinical trials. General and administrative expenses also rose to $22.1 million for the nine months, reflecting increased personnel costs and operational expenses associated with being a public company.

In terms of liquidity, Rapport Therapeutics reported cash, cash equivalents, and short-term investments of $513.0 million as of September 30, 2025, a significant increase from $309.8 million at the end of 2024. This increase was bolstered by the completion of an underwritten public offering in September 2025, which generated net proceeds of approximately $269.4 million. The company anticipates that its current cash reserves will be sufficient to fund operations into the second half of 2029, although it acknowledges the need for additional financing to support ongoing and future development activities.

Operationally, Rapport Therapeutics has made strides in its clinical programs, particularly with RAP-219. The company announced positive topline results from its Phase 2a proof-of-concept trial, which met its primary and secondary endpoints, demonstrating a statistically significant reduction in seizure episodes. The company plans to initiate an open-label long-term safety trial for RAP-219 by the end of 2025 and is also exploring the potential of RAP-219 in treating bipolar disorder and peripheral neuropathic pain.

Looking ahead, Rapport Therapeutics remains focused on advancing its clinical trials and expanding its product pipeline. The company plans to hold an end-of-Phase 2 meeting with the U.S. Food and Drug Administration in late 2025, with the goal of moving into Phase 3 trials for RAP-219 in 2026. However, the company continues to face challenges typical of clinical-stage biotechnology firms, including the need for substantial funding and the inherent uncertainties of drug development.